00:00
Growing Money
Growing Money
USD/RUB
EUR/RUB
Releases

CellCarta Expands CDx Network Through Tempus AI Partnership

In a move to bridge the gap between regulatory approval and clinical access, CellCarta has added Tempus AI to its CDx Commercialization Lab Network. The collaboration allows biopharmaceutical sponsors to streamline the deployment of oncology-focused companion diagnostics by leveraging Tempus’s established physician-ordering infrastructure alongside CellCarta’s development pipeline.

CellCarta Expands CDx Network Through Tempus AI Partnership

The partnership marks the second addition to the network, joining Sonic Healthcare USA to bolster CellCarta’s CDx Accelerator Model. This framework supports sponsors through four distinct phases: build, validate, launch, and transfer. By integrating Tempus Hub, the network enables a direct path for routing sample testing and delivering results to healthcare providers, effectively connecting centralized laboratory testing with existing oncology practice workflows.

Ehab A. El-Gabry, Chief Medical Officer at CellCarta, noted that the integration provides a single-site approval strategy that transitions seamlessly into physician access. Christopher Ung, Chief Scientific Business Officer, added that the goal is to remove the friction sponsors typically face when moving from clinical validation to commercial availability. CellCarta plans to continue broadening this network, targeting further expansion across diverse geographic regions and therapeutic areas to ensure that regulatory success translates into practical, patient-facing diagnostic solutions.

Share

Comments (0)

Leave a comment

No comments yet. Be the first!